Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2018; 76(10): 663-667
DOI: 10.1590/0004-282X20180109
Article

Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison

Toxina botulínica A (BT-A) versus laser terapia de baixa potência (LLLT) em enxaqueca crçnica: Uma triagem comparativa
Luana Mazzacoratti Loeb
1   Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Neurologia/Neurocirurgia, São Paulo SP, Brasil;
,
Rebeca Padrão Amorim
1   Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Neurologia/Neurocirurgia, São Paulo SP, Brasil;
,
Maria da Graça Naffah Mazzacoratti
2   Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Bioquímica, São Paulo SP, Brasil;
,
Fulvio Alexandre Scorza
1   Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Neurologia/Neurocirurgia, São Paulo SP, Brasil;
,
Mario Fernando Prieto Peres
3   Hospital Israelita Albert Einstein, São Paulo SP, Brasil.
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ABSTRACT

The aim of this work was to evaluate patients with chronic migraine treated with botulinum toxin A (BT-A) and compare this with low level laser therapy (LLLT), referencing: pain days, pain intensity, intake of drugs/self-medication, anxiety and sleep disorders.

Methods: Patients were randomized into two groups: BT-A group (n = 18) and LLLT group (n = 18). Each patient kept three pain diaries: one before (baseline) (30 days), one during treatment (30 days) and one after the post-treatment phase (30 days). Repeated ANOVA plus the Bonferroni post-test, Student's t test, and factorial analysis were applied, and p < 0.05 was accepted as significant.

Results: Our data showed that both treatments were able to reduce headache days, acute medication intake and decrease the intensity of pain. Anxiety was reduced in the BT-A group, while sleep disturbance was reduced in the LLLT group.

Conclusion: Our data showed that both treatments can be used to treat chronic migraine, without notable differences between them.

RESUMO

O estudo comparou pacientes com cefaleia crçnica (CM) tratados com toxina botulínica A (BT-A) versus terapia a laser de baixa intensidade (LLLT), relativos a: dias de dor, automedicação, nervosismo e distúrbios do sono.

Métodos: Os pacientes foram randomizados em dois grupos: Grupo BT-A (n = 18) e Grupo LLLT (n = 18). Cada paciente preencheu três diários de dor, sendo um antes do início do tratamento (30 dias), durante o tratamento (30 dias) e um após tratamento (30 dias). ANOVA e pós-teste Bonferroni, teste T de Student e análise fatorial foram utilizados e valores de p < 0,05 foram considerados significativos.

Resultados: Ambos os tratamentos foram capazes de reduzir os dias de dor e a ingestão aguda de medicação. Além disso, a ansiedade foi reduzida no grupo BT-A, enquanto que o distúrbio do sono foi reduzido no grupo LLLT.

Conclusão: Nossos resultados mostraram que ambos os tratamentos são eficientes contra CM, sem diferença entre eles.

Keywords:

Migraine disorders - botulism - low level laser therapy

Palavras-chave:

Transtornos de enxaqueca - botulismo - laserterapia de baixa potência

Support

CNPq, FAPESP, CAPES, Instituto Nacional de Neurociência Translacional (INNT).




Publication History

Received: 04 April 2018

Accepted: 11 July 2018

Article published online:
22 August 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Peres MF, Sanchez del Rio M, Seabra ML, Tufik S, Abucham J, Cipolla-Neto J et al. Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry. 2001 Dec;71(6):747-51. https://doi.org/10.1136/jnnp.71.6.747
  • 2 Barbanti P, Egeo G, Fofi L, Aurilia C, Piroso S. Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine. Neurol Sci. 2015 May;36(1 Suppl 1):29-32. https://doi.org/10.1007/s10072-015-2195-0
  • 3 Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015 Apr;35(17):6619-29. https://doi.org/10.1523/JNEUROSCI.0373-15.2015
  • 4 Suhnan AP, Finch PM, Drummond PD. Hyperacusis in chronic pain: neural interactions between the auditory and nociceptive systems. Int J Audiol. 2017 Nov;56(11):801-9. https://doi.org/10.1080/14992027.2017.1346303
  • 5 Diener HC. Occipital nerve stimulation for chronic migraine: already advised? Cephalalgia. 2012 Oct;32(16):1163-4. https://doi.org/10.1177/0333102412464124
  • 6 Pedraza MI, Cruz C, Ruiz M, López-Mesonero L, Martínez E, Lera M et al. OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. Springerplus. 2015 Apr;4(1):176-80. https://doi.org/10.1186/s40064-015-0957-z
  • 7 Schulman EA1. Lake AE 3rd, Goadsby PJ, Peterlin BL, Siegel SE, Markley HG, Lipton RB. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008 Jun;48(6):77.
  • 8 Garza I, Robertson CE. Critical analysis of the use of onbotulinumtoxin A (botulinum toxin type A in migraine. Neuropsychiatr Dis Treat. 2012;2012(8):35-48.
  • 9 Hashmi JT, Huang YY, Osmani BZ, Sharma SK, Naeser MA, Hamblin MR. Role of low-level laser therapy in neurorehabilitation. PM R. 2010 Dec;2(12 Suppl 2):S292-305. https://doi.org/10.1016/j.pmrj.2010.10.013
  • 10 Nesioonpour S, Mokmeli S, Vojdani S, Mohtadi A, Akhondzadeh R, Behaeen K et al. The effect of low-level laser on postoperative pain after tibial fracture surgery: a double-blind controlled randomized clinical trial. Anesth Pain Med. 2014 Jun;4(3):e17350. https://doi.org/10.5812/aapm.17350
  • 11 Falaki F, Nejat AH, Dalirsani Z. the effect of low-level laser therapy on trigeminal neuralgia: a review of literature. J Dent Res Dent Clin Dent Prospects. 2014;8(1):1-5.
  • 12 Cotler HB, Chow RT, Hamblin MR, Carroll J. The use of low levels laser therapy (LLLT) for musculoskeletal pain. MOJ Orthop Rheumatol. 2015;2(5):00068. https://doi.org/10.15406/mojor.2015.02.00068
  • 13 Verhagen AP, Schellingerhout JM. Low-level laser therapy for neck pain. Lancet. 2010 Feb;375(9716):721. https://doi.org/10.1016/S0140-6736(10)60296-6
  • 14 Chow RT, Johnson MI, Lopes Martins RA, Bjordal JM. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomized placebo or active-treatment controlled trials. Lancet. 2009;374(9705):1897-908.
  • 15 Farivar S, Malekshahabi T, Shiari R. Biological effects of low level laser therapy. J Lasers Med Sci. 2014;5(2):58-62.
  • 16 Allergan. Allergan Patent Notices. Botox®. Madison: Allergan; 2013 Available from: http://www.allergan.com/products/patent_notices, 2013
  • 17 Huang YY, Chen AC, Carroll JD, Hamblin MR and Huang YY. Biphasic dose response in low levels light therapy. 2009;7(4):358-83.) https://doi.org/10.2203/dose-response.09-027.Hamblin